Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma

Rationale: Phenotypic distinctions between severe asthma (SA) and nonsevere asthma (NONSA) may be confounded by differential adherence or incorrect use of corticosteroids. Objectives: To determine if there are persistent phenotypic distinctions between SA (as defined by 2014 American Thoracic Society/European Respiratory Society guidelines) and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors of a corticosteroid response in these populations. Methods: A total of 526 adults age 18 years and older (315 SA) and 188 children age 6 to less than 18 years (107 SA) in the NHLBI Severe Asthma Research Program III were characterized before and 3 weeks after TA. The primary outcome for corticosteroid response was defined as greater than or equal to 10‐point improvement in percent predicted FEV1. Measurements and Main Results: Adult asthma groups exhibited a small but significant mean FEV1% predicted improvement after TA (SA group mean difference, 3.4%; 95% confidence interval, 2.2‐4.7%; P = 0.001), whereas children did not. Adult SA continued to manifest lower FEV1 and worse asthma control as compared with NONSA after TA. In children, after TA only prebronchodilator FEV1 distinguished SA from NONSA. A total of 21% of adults with SA and 20% of children with SA achieved greater than or equal to 10% improvement after TA. Baseline bronchodilator response and fractional exhaled nitric oxide had good sensitivity and specificity for predicting response in all groups except children with NONSA. Conclusions: One in five patients with SA exhibit greater than or equal to 10% improvement in FEV1 with parenteral corticosteroid. Those likely to respond had greater bronchodilator responsiveness and fractional exhaled nitric oxide levels. In adults, differences in airflow obstruction and symptoms between SA and NONSA persist after parenteral corticosteroids, suggesting a component of corticosteroid nonresponsive pathobiology in adults with SA that may differ in children. Clinical trial registered with www.clinicaltrials.gov (NCT 01606826).

[1]  A. Bush,et al.  Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. , 2016, The Journal of allergy and clinical immunology.

[2]  M. Braddock,et al.  Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma. , 2016, American journal of respiratory and critical care medicine.

[3]  B. Cooper,et al.  Improved criterion for assessing lung function reversibility. , 2015, Chest.

[4]  W. Busse,et al.  Asthma Is More Severe in Older Adults , 2015, PloS one.

[5]  D. Postma,et al.  Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. , 2015, American journal of respiratory and critical care medicine.

[6]  R. Pellegrino,et al.  Point: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? Yes. , 2014, Chest.

[7]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[8]  S. Dahlén,et al.  Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. , 2013, Respiratory medicine.

[9]  E. Israel,et al.  Exhaled breath condensate eicosanoid levels associate with asthma and its severity. , 2013, The Journal of allergy and clinical immunology.

[10]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[11]  V. Fainardi,et al.  Ethnic variation in response to intramuscular triamcinolone in children with severe therapy resistant asthma , 2012 .

[12]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[13]  Mario Castro,et al.  Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. , 2012, American journal of respiratory and critical care medicine.

[14]  Lee， Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[15]  E. Israel,et al.  Active albuterol or placebo, sham acupuncture, or no intervention in asthma. , 2011, The New England journal of medicine.

[16]  E. Juniper,et al.  Asthma Control Questionnaire in children: validation, measurement properties, interpretation , 2010, European Respiratory Journal.

[17]  Deborah A Meyers,et al.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. , 2010, The Journal of allergy and clinical immunology.

[18]  Sheng-hua Wu,et al.  Reversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degree , 2010, Pediatric pulmonology.

[19]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[20]  M. Rosenthal,et al.  Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma , 2009, European Respiratory Journal.

[21]  Richard J Martin,et al.  Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. , 2007, The Journal of allergy and clinical immunology.

[22]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[23]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[24]  G. Viegi,et al.  Coming together: the ATS/ERS consensus on clinical pulmonary function testing , 2005, European Respiratory Journal.

[25]  J. Hankinson,et al.  General considerations for lung function testing , 2005, European Respiratory Journal.

[26]  A. Zwinderman,et al.  "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. , 2004, American journal of respiratory and critical care medicine.

[27]  D. Postma,et al.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma , 2003, European Respiratory Journal.

[28]  P. Sterk,et al.  Standardised methodology of sputum induction and processing , 2002, European Respiratory Journal.

[29]  S. Szefler,et al.  Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. , 1998, The Journal of allergy and clinical immunology.

[30]  Y. B. Cho,et al.  Interpretation of Bronchodilator Response inPatients with Obstructive Airway Disease , 1995 .

[31]  D. Postma,et al.  Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. , 1992, Thorax.

[32]  V. Fainardi,et al.  Ethnic Variation in Response to IM Triamcinolone in Children With Severe Therapy-Resistant Asthma. , 2016, Chest.

[33]  S. Willsie.  An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications , 2012 .

[34]  William W Busse,et al.  Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. , 2011, The Journal of allergy and clinical immunology.

[35]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[36]  A. Coates,et al.  ‘ ‘ ATS / ERS TASK FORCE : STANDARDISATION OF LUNG FUNCTION TESTING , 2005 .

[37]  V. Popa.  ATS guidelines for methacholine and exercise challenge testing. , 2001, American journal of respiratory and critical care medicine.